目的 探讨金丝桃苷对代谢相关脂肪性肝病（MAFLD）的保护作用。方法 将36只ApoE^-/-小鼠，随机分为模型组、金丝桃苷（200 mg/kg）组和辛伐他汀（阳性对照药，5.2 mg/kg）组，每组12只；另将12只C57BL/6小鼠作为对照组。对照组给予普通饲料，其他3组均给予高脂饲料构建MAFLD模型，同时每天ig给药2次，对照组和模型组ig 0.5% CMC-Na溶液，连续给药12周。HE染色法观察小鼠肝脏组织病理变化；油红O染色法观察小鼠肝脏组织内脂肪沉积情况；全血项分析仪检测小鼠血清总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、天冬氨酸氨基转移酶（AST）和丙氨酸氨基转移酶（ALT）含量；ELISA法检测小鼠肝组织丙二醛（MDA）、超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平。结果 与模型组比较，金丝桃苷可以减小模型小鼠肝脏细胞空洞和炎症浸润；显著改善脂质沉积（P<0.01）；显著降低血清LDL-C、AST、ALT水平（P<0.01）；显著降低肝脏MDA、IL-6和TNF-α水平（P<0.01），显著升高肝脏SOD和GSH-Px水平（P<0.05、0.01）。结论 金丝桃苷通过减少脂质囤积、减轻氧化应激、抑制炎症反应发挥对MAFLD的保护作用。

Objective To explore the protective effect of hyperoside on non-alcoholic fatty liver disease. Methods Thirty-six ApoE-/- mice were randomly divided into model group, hyperin (200 mg/kg) group and simvastatin (positive control drug, 5.2 mg/kg) group, with 12 mice in each group. Another 12 C57BL/6 mice were used as control group. The control group was given ordinary diet, and the other three groups were given high-fat diet to construct the MAFLD model, and the control group and the model group were given 0.5% CMC-Na solution intragaally twice a day, for 12 weeks. HE staining method was used to observe the pathological changes of mouse liver. Oil red O staining method to observe the fat content in mouse liver tissue. Whole blood analyzer to detect total cholesterol (TC), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) in mouse serum , Low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) content. ELISA method was used to detect malondialdehyde (MDA) and superoxide dismutase (SOD) in mouse liver tissue, glutathione peroxidase (GSH-Px), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) content. Results Hyperoside can reduce the area of cavities and inflammatory infiltration of mouse liver cells and improve the condition of lipid deposition (P < 0.01). Hyperin significantly decreased the serum levels of TC, LDL-C, HDL-C, AST and ALT (P < 0.01), decreased the levels of MDA, IL-6 and TNF-α in liversignificantly (P < 0.01), and increased the levels of SOD and GSH-Px in liver significantly (P < 0.05, 0.01). Conclusion Hyperin can slow down the pathological process of non-alcoholic fatty liver disease, and its protective effect may be achieved by reducing lipid accumulation, reducing oxidative stress, and inhibiting inflammation.

R285.5

辽宁省自然科学基金面上项目（2015010708）